🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against drug-resistant strains of the infection, according to health experts.

An International Challenge

Cases of gonorrhoea are escalating worldwide, with data suggesting in excess of 82 million new cases annually. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

According to findings detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which involves a dual-drug approach. The study involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in numerous regions with limited resources.

Clinicians directly involved have expressed positive views. Access to a one-pill regimen such as this is seen as a "revolutionary step" for public health efforts. This is viewed as vital to alleviate the strain of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.